Immuno-Oncology Biotech Aduro Boosts IPO Target To $119M
Venture capital-backed Aduro Biotech heightened expectations Tuesday for its upcoming initial public offering to $119 million, suggesting investors are anxious to snap up a piece of the immuno-oncology biotech, which has...To view the full article, register now.
Already a subscriber? Click here to view full article